References
- Janoff A. S., Boni L. T., Popescu M. C., Minchey S. R., Cullis P. R., Madden T. D., Taraschi T., Gruner S. M., Shyamsunder E., Tate M. W., Mendelsohn R., Bonner D. Unusual lipid structures selectively reduce the toxicity of Amphotericin B. Proc. Natl. Acad. Set. USA 1988; 85: 6122–6126
- Jensen G. M., Skenes C. R., Bunch T. H., Weissman C. A., Amirghahari N., Sato-Rius A., Moynihan K. L., Eley C. G.S. Determination of the relative toxicity of amphotericin B formulations: A red blood cell potassium release assay. Drug Delivery 1999; 6: 81–88
- Janoff A. S., Perkins W. R., Saletan S. L., Swenson C. E. Amphotericin B lipid complex (ABLC®): A molecular rationale for the attenuation of amphotericin B related toxicities. J. Lipo. Res. 1993; 3: 451–471
- Adler-Moore J. P., Proffitt R. T. Development, characterization, efficacy and mode of action of Ambisome® a unilamellar liposomal formulation of amphotericin B. J. Lipo. Res. 1993; 3: 429–450
- Guo L. S. S., Working P. K. Complexes of amphotericin B and cholesteryl sulfate. J. Lipo. Res. 1993; 3: 473–490
- Singh R. M., Perdue B. E. Amphotericin B: A class review. Formulary 1998; 33: 424–447
- Bhamra R., Sa'ad A., Bolcsak L. E., Janoff A. S., Swenson C. E. Behavior of amphotericin B lipid complex in plasma in vitro and in the circulation of rats. Antimicrob. Agents Chemother. 1997; 41: 886–892
- Olsen S. J., Swerdel M. R., Blue B., Clark J. M., Bonner DP. Tissue distribution of amphotericin B lipid complex in laboratory animals. J. Pharm. Pharmacol. 1991; 43: 831–835
- Williams P., Waskin H., Bolcsak L., Swenson C. Amphotericin B concentrations in autopsy tissues of organ transplant patients administered amphotericin B lipid complex injection. 18th Annual meeting. American Society of Transplantation, Chicago, lll May 15-19, 1999/1999; 348
- Adcdoyin A., Bernardo J. F., Swenson C. E., Bolcsak L. E., Horwith G., DeWit S., Kelly E., Klastersky J., Sculier J. P., DeValeriola D., Anassie E., Lopez-Berestein G., Llanos-Cuentas A., Boyle A., Branch R. A. Pharmacokinetic profile of Abelcet (amphotericin B lipid complex injection): Combined experience from phase I and phase 11 studies. Antimicrob. Agents Chemother. 1997; 41: 2201–2208